- By Kristi Powers
Anderson Ata is a typical 10-year-old who likes playing basketball and hanging out with his friends, but on New Year’s Eve he got really sick.
“I took a couple of covers from my cabinet and put them on me, waited about an hour and I was still shaking and I didn’t know what was happening,” Anderson Ata explained to FOX 35 News Anchor Amy Kaufeldt.
Doctors diagnosed Anderson with early stages of Type 1 diabetes. The family was referred to Dr. Konda Reddy to administer the life-changing monoclonal antibody treatment. Anderson became the seventh patient in the world, and the first in Orlando, to receive the new FDA-approved drug called Tzield.
To determine eligibility for the treatment, a simple blood test is performed. TZIELD, is the first drug that can delay the progression of Type 1 diabetes by up to three years in adults and up to eight years in children.
AdventHealth was a part of a large global research study which led to TZIELD gaining FDA-approval. When TZIELD became available on the market at the beginning of the year, AdventHealth was one of a handful of hospital systems administering the groundbreaking treatment.
Learn more about how the treatment is given and how Anderson is doing post treatment, here.
Choose the health content that’s right for you, and get it delivered right in your inbox.
Recent News
-
Business
In this episode of the Inspiring Wholeness podcast, Orlando Mayor Buddy Dyer joins Doug Harcombe, CEO, AdventHealth Central Florida South Market/AdventHealth Lake Nona, to explore plans for the...
-
Health Care
The Baby Place® at AdventHealth Altamonte Springs, is home to Central Florida’s first hospital-based low-intervention birthing suite.
-
Business
Dr. Andrew Weinfeld will be responsible for executing clinical and organizational strategy, improving clinical effectiveness and patient safety, and delivering exceptional patient experiences for the...